Scholarlink

Introduction <p>Guidance from the Aiming Higher in Eczema/Atopic Dermatitis initiative identified moderate and optimal treatment targets for clinician-reported outcomes (ClinROs) and patient-reported outcomes (PROs) and defined minimal disease activity (MDA) as simultaneously meeting optimal targets in ClinRO and PRO. This post hoc analysis investigates the impact of achieving individual optimal targets or MDA on patient health-related quality of life (HRQoL) outcomes in patients with atopic dermatitis.</p> Methods <p>Patients from phase 3 Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and AD UP (NCT03568318) were randomized 1:1:1 to receive daily oral upadacitinib at either 15&#xa0;mg or 30&#xa0;mg, or placebo for the first 16&#xa0;weeks. Patients were pooled for this analysis regardless of intervention and stratified into three mutually exclusive response groups meeting optimal, moderate, or neither treatment target for each ClinRO or PRO, and the achievement of MDA at week 16. Impact on the patient’s HRQoL was measured across eight outcomes: itch, skin symptoms, quality of life, sleep, daily activities, emotional state, work productivity, and treatment satisfaction.</p> Results <p>Patients who achieved optimal treatment targets, compared with those achieving moderate or neither treatment target, reported greater improvement in patient HRQoL outcomes (1.1–20.2-fold for optimal versus moderate, 1.3 to &gt; 50-fold for optimal versus neither target, and 1.2–16.3-fold for moderate versus neither target groups). In addition, patients who achieved MDA, versus those achieving optimal ClinRO or PRO alone, were more likely to report improved patient HRQoL outcomes.</p> Conclusions <p>These results highlight the value of reaching optimal treatment targets and MDA in disease management of atopic dermatitis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic Dermatitis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月26日

查看全文
  • Jonathan I. Silverberg,
  • Melinda Gooderham,
  • Andreas Wollenberg,
  • Andrew E. Pink,
  • Diego Ruiz Dasilva,
  • Shawn G. Kwatra,
  • Yousef Binamer,
  • Norito Katoh,
  • Valeria Aoki,
  • Alvaro Moreira,
  • Ayman Grada,
  • Chao Li,
  • Brian Calimlim,
  • Wan-Ju Lee,
  • Christopher G. Bunick

摘要

Introduction

Guidance from the Aiming Higher in Eczema/Atopic Dermatitis initiative identified moderate and optimal treatment targets for clinician-reported outcomes (ClinROs) and patient-reported outcomes (PROs) and defined minimal disease activity (MDA) as simultaneously meeting optimal targets in ClinRO and PRO. This post hoc analysis investigates the impact of achieving individual optimal targets or MDA on patient health-related quality of life (HRQoL) outcomes in patients with atopic dermatitis.

Methods

Patients from phase 3 Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and AD UP (NCT03568318) were randomized 1:1:1 to receive daily oral upadacitinib at either 15 mg or 30 mg, or placebo for the first 16 weeks. Patients were pooled for this analysis regardless of intervention and stratified into three mutually exclusive response groups meeting optimal, moderate, or neither treatment target for each ClinRO or PRO, and the achievement of MDA at week 16. Impact on the patient’s HRQoL was measured across eight outcomes: itch, skin symptoms, quality of life, sleep, daily activities, emotional state, work productivity, and treatment satisfaction.

Results

Patients who achieved optimal treatment targets, compared with those achieving moderate or neither treatment target, reported greater improvement in patient HRQoL outcomes (1.1–20.2-fold for optimal versus moderate, 1.3 to > 50-fold for optimal versus neither target, and 1.2–16.3-fold for moderate versus neither target groups). In addition, patients who achieved MDA, versus those achieving optimal ClinRO or PRO alone, were more likely to report improved patient HRQoL outcomes.

Conclusions

These results highlight the value of reaching optimal treatment targets and MDA in disease management of atopic dermatitis.